title: Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif.
abstract: We have developed a potential tumor-targeting peptide vector (cRGD-hK) that is intended to be systemically and repeatedly administered to patients with advanced solid tumors. The peptide vector of 36 l-amino acid residues, CRGDCF(K[H-]KKK)6, comprises a tumor-homing RGD motif, a DNA-binding oligolysine, and histidyl residues to facilitate the delivery into the cytosol. Using cytomegalovirus-driven luciferase expression plasmids as a reporter, we tested the transfection efficiency of cRGD-hK in hepatoma and pancreatic cancer cell lines. Transfection with the cRGD-hK/plasmid complexes (molar ratio 4000:1) was inhibited by 50 nM bafilomycin A1, an inhibitor of the vacuolar ATPase endosomal proton pump, or 10 microM cycloRGDfV, an integrin alphavbeta3 antagonist, indicating that the three elements of cRGD-hK could function as expected, at least in vitro. In nude mice bearing tumors created by subcutaneous inoculation, luciferase activity in the tumor tissues 48 hours after the injection of the cRGD-hK/plasmid complexes through the tail vein (20 microg plasmids per mouse) was significantly higher than that in the lung, kidney, and spleen, but only slightly higher than that in the liver. Although the latter difference was small, we propose a potential nonviral gene therapy for advanced solid tumors through use of the tumor-targeting peptide vector.
authors.affiliation: The Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. yaoki55@hsp.md.shinshu-u.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Aoki
authors.forename: S
authors.initials: S
authors.lastname: Hosaka
authors.forename: S
authors.initials: S
authors.lastname: Kawa
authors.forename: K
authors.initials: K
authors.lastname: Kiyosawa
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006639:Histidine; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008156:Luciferases / Q000378:metabolism; D018942:Macrolides; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009842:Oligopeptides / Q000235:genetics* / Q000493:pharmacokinetics; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010957:Plasmids; D011107:Polylysine / Q000235:genetics* / Q000493:pharmacokinetics; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
chemical_list: D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D018942:Macrolides; D009842:Oligopeptides; D011107:Polylysine; D006639:Histidine; C047981:arginyl-glycyl-aspartic acid; C040929:bafilomycin A1; D008156:Luciferases; D006180:Proton-Translocating ATPases